Skip to main content
SpringerLink
Log in

Paliperidone Extended-Release: Safety and Tolerability from a Metabolic Profile Perspective

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Pharmacologic management strategies for schizophrenia, a relatively common psychotic disorder, include the use of typical and atypical antipsychotic drugs. In general, typical (or conventional) antipsychotics have a proven track record in effectively managing the positive symptoms of schizophrenia but sometimes lack efficacy in treating negative symptoms. The conventional agents are also associated with adverse neurologic effects such as extrapyramidal symptoms (EPS). The development of atypical antipsychotics has partly ameliorated the issue of EPS induced by typical antipsychotics. However, several of these atypical antipsychotic agents have been associated with adverse metabolic effects, including weight gain, dyslipidemia, and increased serum glucose levels. Paliperidone (9-hydroxy-riperidone) extended-release (ER) is an atypical antipsychotic indicated for the treatment of schizophrenia which utilizes a patented oral osmotic system technology that provides constant drug delivery over the course of the day. The efficacy and safety of paliperidone ER in patients with schizophrenia have been established. This review focuses on the metabolic safety of paliperidone ER in patients with schizophrenia. Clinical trials have demonstrated a lack of significant change in lipid profiles with paliperidone ER; furthermore, reported incidences of glucose-related adverse events in clinical trials were very low and similar to those seen with placebo. While dose-related increases in bodyweight of 1–2 kg have been observed with paliperidone ER, there are few reports of clinically relevant increases in bodyweight during treatment. Placebo-controlled trials indicate that the risk of developing metabolic disorders with paliperidone ER is low and similar to that seen with placebo. Furthermore, the ER formulation of paliperidone may offer potential advantages over atypical antipsychotics such as risperidone, particularly with regard to side effects and compliance, but comparative studies are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet. 1995;346(8973):477–81.

    Article  PubMed  CAS  Google Scholar 

  2. Buckley PF. Treatment of schizophrenia: let’s talk dollars and sense. Am J Manag Care. 1998;4(3):369–83.

    PubMed  CAS  Google Scholar 

  3. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs. 2008;68(16):2269–92.

    Article  PubMed  CAS  Google Scholar 

  4. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56.

    PubMed  Google Scholar 

  5. Ellenbroek BA. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther. 1993;57(1):1–78.

    PubMed  CAS  Google Scholar 

  6. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124(1–2):57–73.

    Article  CAS  Google Scholar 

  7. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251(1):238–46.

    PubMed  CAS  Google Scholar 

  8. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989;25(3):390–2.

    PubMed  CAS  Google Scholar 

  9. Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry. 2001;62(Suppl 7):4–10.

    PubMed  CAS  Google Scholar 

  10. Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf. 2001;24(1):59–73.

    Article  PubMed  CAS  Google Scholar 

  11. Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin. 2008;24(12):3341–55.

    Article  PubMed  CAS  Google Scholar 

  12. Fagan AL, Kissack JC, Augustin BG. Adverse events medication treatment costs in a chronically, severely mentally ill forensics population. Clin Schizophr Relat Psychoses. 2008;2(2):158–62.

    Article  Google Scholar 

  13. Canuso CM, Youssef EA, Bossie CA, et al. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol. 2008;23(4):209–15.

    Article  PubMed  Google Scholar 

  14. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64(5):598–604.

    Article  PubMed  CAS  Google Scholar 

  15. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1–3):147–61.

    Article  PubMed  CAS  Google Scholar 

  16. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46(3):273–81.

    PubMed  CAS  Google Scholar 

  17. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27–35.

    Article  PubMed  CAS  Google Scholar 

  18. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63(10):856–65.

    Article  PubMed  CAS  Google Scholar 

  19. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70(1):1–17.

    Article  PubMed  Google Scholar 

  20. Hardy TA, Marquez E, Kryzhanovskaya L, et al. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. J Clin Psychopharmacol. 2006;26(4):405–8.

    Article  PubMed  CAS  Google Scholar 

  21. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5):425–33.

    Article  PubMed  CAS  Google Scholar 

  22. Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl). 2005;183(3):383–6.

    Article  CAS  Google Scholar 

  23. Wu RR, Zhao JP, Zhai JG, et al. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol. 2007;27(4):374–9.

    Article  PubMed  Google Scholar 

  24. Khalili H, Dashti-Khavidaki S, Okhovatpour H, et al. Effects of risperidone on lipid profile. Ann Pharmacother. 2007;41(5):899–900.

    Article  PubMed  Google Scholar 

  25. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;62(Suppl 23):30–8.

    PubMed  CAS  Google Scholar 

  26. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–96.

    PubMed  CAS  Google Scholar 

  27. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93.

    PubMed  CAS  Google Scholar 

  28. Schooler NR, Gharabawi G, Bossie C, et al. A “virtual” comparison of paliperidone ER and oral risperidone in patients with schizophrenia [abstract]. 45th Annual Meeting of the American College of Neuropharmacology. 2006 Dec 3–7, Hollywood, p. S241–42.

  29. Liberty IF, Todder D, Umansky R, et al. Atypical antipsychotics and diabetes mellitus: an association. Isr Med Assoc J. 2004;6(5):276–9.

    PubMed  CAS  Google Scholar 

  30. Buckley PF. Update on the treatment and management of schizophrenia and bipolar disorder. CNS Spectr. 2008;13(2 Suppl 1):1–10 (quiz 1–2).

  31. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519–26.

    Article  PubMed  CAS  Google Scholar 

  32. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet. 2005;20(5):368–78.

    Article  PubMed  CAS  Google Scholar 

  33. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1–3):117–30.

    Article  PubMed  Google Scholar 

  34. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363–70.

    Article  PubMed  CAS  Google Scholar 

  35. Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008;69(5):817–29.

    Article  PubMed  CAS  Google Scholar 

  36. Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol. 2008;23(6):343–56.

    Article  PubMed  Google Scholar 

  37. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Invega™ (paliperidone) extended-release tablets: US prescribing information [online]. Available from http://invega.com/assets/prescribing-information.pdf. Accessed 24 May 2011.

  38. European Medicines Agency. Invega™ (paliperidone): summary of product characteristics. 2006. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000746/WC500034925.pdf. Accessed 21 Oct 2013.

  39. Luthringer R, Staner L, Noel N, et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol. 2007;22(5):299–308.

    Article  PubMed  Google Scholar 

  40. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry. 2008;16(1):31–43.

    Article  PubMed  Google Scholar 

  41. Schreiner A, Tessier C, Hoeben D, et al. A prospective randomized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia. 15th Winter Workshop in Psychoses (WWP); 2009 Nov 15–18; Barcelona.

  42. Jeppesen J, Hein HO, Suadicani P, et al. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med. 2001;161(3):361–6.

    Article  PubMed  CAS  Google Scholar 

  43. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(1):6–14.

    Article  PubMed  CAS  Google Scholar 

  44. European Medicines Agency. Risperdal (risperidone): summary of product characteristics. 2011. http://www.medicines.org.uk/EMC/medicine/12818/SPC/Risperdal+Tablets,+Liquid+%26+Quicklet/. Accessed 24 Oct 2013.

  45. Jones MP, Nicholl D, Trakas K. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther. 2010;48(6):383–99.

    Article  PubMed  CAS  Google Scholar 

  46. Janicak PG, Winans EA. Paliperidone ER: a review of the clinical trial data. Neuropsychiatr Dis Treat. 2007;3(6):869–97.

    PubMed  CAS  Google Scholar 

  47. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65(Suppl 18):27–35.

    PubMed  CAS  Google Scholar 

  48. Citrome L. Paliperidone: quo vadis? Int J Clin Pract. 2007;61(4):653–62.

    Article  PubMed  CAS  Google Scholar 

  49. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36(4):769–79.

    Article  PubMed  CAS  Google Scholar 

  50. Degmecic D, Pozgain I, Filakovic P. Psychoeducation and compliance in the treatment of patients with schizophrenia. Coll Antropol. 2007;31(4):1111–5.

    PubMed  Google Scholar 

  51. Janicak PG, Wu JH, Mao L. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials. Curr Med Res Opin. 2008;24(6):1807–15.

    Article  PubMed  Google Scholar 

  52. Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007;23(10):2305–12.

    Article  PubMed  Google Scholar 

  53. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl). 1996;124(1–2):2–34.

    Article  CAS  Google Scholar 

  54. Schreiner A, Niehaus D, Shuriquie NA, et al. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacol. 2012;32(4):449–57.

    Article  PubMed  CAS  Google Scholar 

  55. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998;18(2):63–101.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Stephanie Blick and Simone Boniface of inScience Communications, Springer Healthcare, for medical writing assistance in the preparation of this manuscript. This assistance was funded by Janssen-Cilag, Spain. Carlos Quilo is an employee of Janssen Cilag, Spain. Alfonso Rodríguez Martínez declares no conflicts of interest pertaining to this manuscript.

Author information

Authors and Affiliations

  1. Centro Forum, C/ Llull 410, 08019, Barcelona, Spain

    Alfonso Rodríguez-Martínez

  2. Medical Department, Janssen Cilag, Madrid, Spain

    Carlos Guzmán Quilo

Authors
  1. Alfonso Rodríguez-Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Guzmán Quilo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alfonso Rodríguez-Martínez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodríguez-Martínez, A., Quilo, C.G. Paliperidone Extended-Release: Safety and Tolerability from a Metabolic Profile Perspective. Clin Drug Investig 33, 867–876 (2013). https://doi.org/10.1007/s40261-013-0100-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-013-0100-2

Keywords

Search

Navigation